A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.

被引：0
|
作者：
Burris, H. A.
Krop, I. E.
Modi, S.
Rodon, J.
Lutzker, S. G.
Holden, S. N.
Bhattacharya, S.
Sliwkowski, M. X.
Beeram, M.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Int Drug Dev, San Antonio, TX USA
[5] Genentech Inc, San Francisco, CA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [2] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [3] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [4] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [5] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [6] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I.
    Modi, S.
    Tolcher, A.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S.
    Lutzker, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Trastuzumab-MCC-DM1 (TMAB-MCC-DM1), a first-in-class her2 antibody-drug conjugate (ADC) - A phase I study in patients (PTS) with Her2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I. E.
    Modi, S.
    Tolcher, A. W.
    Tibbitts, J.
    Rabbees, N.
    Girish, S.
    Lutzker, S. G.
    Holden, S. N.
    Burris, H. A.
    ANNALS OF ONCOLOGY, 2007, 18 : 21 - 21
  • [8] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
    Beeram, M.
    Burris, H. A., III
    Modi, S.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Krop, I. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
    Pegram, Mark D.
    Miles, David
    Tsui, C. Kimberly
    Zong, Yu
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 775 - 786
  • [10] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
12345